Lupin Limited has informed the Exchange that Board of Directors at its meeting held on May 07, 2026, recommended Final Dividend of Rs. 18 per equity share.
LUPIN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.5 pts less than Nifty Midcap 150 and 3.7 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Lupin Limited reported strong FY26 results with standalone net profit of Rs 63.67 billion, up 60% from Rs 39.73 billion in FY25. Consolidated net profit grew 62% to Rs 53.55 billion. The Board recommended a final dividend of Rs 18 per equity share (900% of face value Rs 2), aggregating Rs 8.23 billion, subject to shareholder approval at the ensuing AGM. Total standalone revenue for FY26 was Rs 195.13 billion (up 15% YoY) while consolidated revenue reached Rs 279.58 billion (up 23% YoY). The company also completed acquisitions of VISUfarma B.V. and Renascience Pharma Limited during the year.
The dividend of Rs 18 per share represents approximately 13% payout ratio on FY26 standalone EPS of Rs 139.38, indicating sustainable returns. Strong 60%+ profit growth and healthy cash generation from operations of Rs 73.35 billion (consolidated) are positive signals for shareholders.